Key Insider and Spouse Disclose 6.33% Stake in Gyre Therapeutics Post-Merger

summarizeSummary

Songjiang Ma and his spouse, Yueying Zhu, have disclosed a combined 6.33% beneficial ownership in Gyre Therapeutics, including exercisable options, following the company's acquisition of Cullgen Inc.

check_boxKey Events

• Beneficial Ownership Update

  Songjiang Ma and Yueying Zhu now beneficially own 7,342,131 shares, representing 6.33% of Gyre Therapeutics' common stock.

• Post-Merger Disclosure

  This amendment updates their ownership following the May 4, 2026, completion of the $300 million all-stock acquisition of Cullgen Inc.

• Insider Stake

  The reported ownership includes 4,536,047 shares underlying options exercisable by Mr. Ma within 60 days, indicating a significant potential stake by a key insider.

auto_awesomeAnalysis

This Schedule 13D/A updates the beneficial ownership of Songjiang Ma and Yueying Zhu, revealing their combined 6.33% stake in Gyre Therapeutics. This disclosure follows the company's recent $300 million all-stock acquisition of Cullgen Inc. While Ma and Zhu did not receive new shares in the merger, the increase in outstanding shares necessitated this update to their percentage ownership. The stake, valued at approximately $58.5 million, includes 4.5 million shares underlying options exercisable by Mr. Ma, indicating a significant long-term interest by a key insider. This filing provides further clarity on the post-merger ownership structure, complementing other recent 13D/A filings that detailed new controlling shareholders and significant stakes by Cullgen figures.